measles, mumps, and rubella vaccine (MMR) Report issue

Vaccine Approved FDA
AACT PubChem

Active Ingredient History

NOW
  • Now
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

attenuated measles mumps rubella | measles, mumps and rubella combined vaccine, live | measles, mumps and rubella vaccine | measles, mumps, and rubella vaccine | measles, mumps, and rubella virus vaccine live | measles, mumps, and rubella virus vaccine, live | measles virus enders edmonston strain (live, attenuated) / mumps virus jeryl lynn (level b) strain (live, attenuated) / rubella virus wistar ra 27/3 strain (live, attenuated) | mmr | mmrii | mmr ii | mmr-v | mmr vaxpro | mumps vaccine | trivivac vaccine | v419

Organizations (56)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (53)

Approved Indications (1)


 

Virus Diseases

Experimental Indications - Clinical Trial Phases 1-4 (53)


 

Acute-Phase Reaction (Phase 2/Phase 3)

Arthritis, Juvenile (Phase 4)

Bacterial Infections (Phase 3)

Chickenpox (Phase 4)

Chikungunya Fever (Phase 2)

Communicable Diseases (Phase 2)

Condylomata Acuminata (Phase 3)

COVID-19 (Phase 4)

Dengue (Phase 3)

Diphtheria (Phase 3)

Diphtheria Toxoid (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Eczema (Phase 4)

Encephalitis, Japanese (Phase 3)

Esophageal and Gastric Varices (Phase 2)

Haemophilus influenzae (Phase 2)

Haemophilus influenzae type b (Phase 3)

Healthy Volunteers (Phase 3)

Hepatitis A (Phase 4)

Hepatitis B (Phase 2)

HIV (Phase 4)

HIV Infections (Phase 2)

Human papillomavirus 16 (Phase 4)

Hypersensitivity (Phase 4)

Immune System Diseases (Phase 4)

Infections (Phase 4)

Measles (Phase 4)

Measles-Mumps-Rubella Vaccine (Phase 4)

Meningitis (Phase 3)

Meningitis, Meningococcal (Phase 3)

Meningococcal Infections (Phase 3)

Mumps (Phase 4)

Mumps Vaccine (Phase 2)

Neisseria meningitidis (Phase 3)

Papillomavirus Infections (Phase 4)

Pertussis Vaccine (Phase 3)

Pneumococcal Infections (Phase 3)

Pneumococcal Vaccines (Phase 3)

Poliomyelitis (Phase 4)

Poliovirus Vaccines (Phase 2)

Psoriasis (Phase 1)

Respiratory Tract Infections (Phase 4)

Rotavirus (Phase 4)

Rubella (Phase 4)

Rubella Vaccine (Phase 2)

Severe Dengue (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 3)

Tetanus (Phase 3)

Vaccines (Phase 4)

Virus Diseases (Phase 3)

Warts (Phase 4)

Whooping Cough (Phase 3)

Yellow Fever (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 95
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue